Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study

Korábbi kezelés

• Receipt of another unapproved investigational drug or non-drug treatment within 30 days before the index date or during the observation period.

Más betegség

• History of Grade 3 or higher interstitial lung disease (ILD), or evidence of any clinically active ILD.
• Uncontrolled comorbid diseases or conditions, including but not limited to decompensated respiratory, cardiac, hepatic, or renal disease; ongoing or active infection, including active clinical tuberculosis; renal transplantation; or psychiatric/social conditions that may limit study compliance.

Egyéb

• Unstable brain metastases.
• Inability to comply with the study for any reason.

• Age ≥18 years at the index date.
• Unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
• Documented HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutation.
• Received at least one prior systemic therapy for advanced NSCLC. Prior HER2-targeted antibody-drug conjugate (ADC) therapy is permitted, whereas prior HER2-targeted tyrosine kinase inhibitor (TKI) therapy is not permitted.
• For retrospectively included participants, sufficient baseline clinical, treatment, and prior follow-up data are available.
• Sevabertinib treatment has been determined by the treating physician based on clinical practice, or the participant has already initiated sevabertinib at screening.